High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana

Tropical Medicine and International Health

Volumn 10, Issue 12, 2005, Pages 1271-1273

  Röwer, Susanne ^a,e   Bienzle, Ulrich ^a,e   Weise, Alexander ^b   Lambertz, Ulrike ^b   Forst, Thomas ^b   Otchwemah, Rowland N ^c   Pfützner, Andreas ^b,d   Mockenhaupt, Frank P ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IKFE   (Germany)

^c UNIVERSITY FOR DEVELOPMENT STUDIES   (Ghana)

^d UNIVERSITY OF APPLIED SCIENCES   (Germany)

^e Institute of Tropical Medicine   (Germany)

Author keywords

Adverse effects; Amodiaquine; CYP2C8 variants; Ghanaian children

Indexed keywords

AMODIAQUINE; CYTOCHROME P450; CYTOCHROME P450 2C8; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; CYP2C8 PROTEIN, HUMAN; PRODRUG; SESQUITERPENE; UNSPECIFIC MONOOXYGENASE;

CYTOCHROME; DISEASE PREVALENCE; MALARIA; MUTATION;

ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GHANA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALE; PREVALENCE; DRUG COMBINATION; GENETIC POLYMORPHISM; GENETICS; MALARIA FALCIPARUM; MUTATION; PRESCHOOL CHILD;

AFRICA; GHANA; SUB-SAHARAN AFRICA; WEST AFRICA;

ARTESUNATE;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; GHANA; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MUTATION; POLYMORPHISM, GENETIC; PREVALENCE; PRODRUGS; SESQUITERPENES;

EID: 29044443860     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2005.01525.x     Document Type: Article

References (22)

1. Bahadur N, Leathart JBS, Mutch E et al. (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochemical Pharmacology 64, 1579-1589.
2. Cavaco I, Strömberg-Nörklit J, Kaneko A et al. (2005) CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. European Journal of Clinical Pharmacology 61, 15-18.
3. Clarke JB, Maggs JL, Kitteringham NR & Park BK (1990) Immunogenicity of amodiaquine in the rat. International Archives of Allergy and Applied Immunology 91, 335-342.
4. Dai D, Zeldin DC, Blaisdell JA et al. (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597-607.
5. Daly AK (2003) Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundamental & Clinical Pharmacology 17, 27-41.
6. Ehrhardt S, Mockenhaupt FP, Agana-Nsiire P et al. (2002) Efficacy of chloroquine in the treatment of uncomplicated Plasmodium falciparum malaria in northern Ghana. Annals of Tropical Medicine and Parasitology 96, 239-247.
7. Harrison AC, Kitteringham NR, Clarke JB & Park BK (1992) The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochemical Pharmacology 43, 1421-1430.
8. Heubi JE, Barbacci MB & Zimmerman HJ (1998) Therapeutic misadventures with acetaminophen: hepatotoxicity after multiple doses in children. Journal of Pediatrics 132, 22-27.
9. Li X-Q, Björkman A, Andersson TB, Ridderström M & Masimirembwa CM (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. The Journal of Pharmacology and Experimental Therapeutics 300, 399-407.
10. Li X-Q, Björkman A, Andersson TB, Gustafsson LL & Masimirembwa MC (2003) Identification of human cytochrome P 450's that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. European Journal of Clinical Pharmacology 59, 429-442.
11. Low DA & Smith A (1976) History of East Africa. Oxford University Press, Oxford, pp. 576-577.
12. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR & Brodie BB (1973) Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. The Journal of Pharmacology and Experimental Therapeutics 187, 211-217.
13. Mockenhaupt FP, Ehrhardt S, Gellert S et al. (2004) Alpha(+)-thalassemia protects African children from severe malaria. Blood 104, 2003-2006.
14. Mockenhaupt FP, Ehrhardt S, Dzisi SY et al. (2005) A randomised, placebo-controlled, and double-blind trial on sulfadoxinepyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Tropical Medicine and International Health 10, 512-520.
15. Naisbitt DJ, Williams DP, O'Neill PM et al. (1998) Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs. Chemical Research in Toxicology 11, 1586-1595.
16. Niagia S (2004) Ghana battles drug-resistant malaria with artesunate. Lancet 363, 1372.
17. O'Neill PM, Mukhtar A, Stocks PA et al. (2003) Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. Journal of Medicinal Chemistry 46, 4933-4945.
18. Oduro AR, Anyorigiya T, Hodgson A et al. (2005) A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. Tropical Medicine and International Health 10, 279-284.
19. Olliaro P, Nevill C, LeBras J et al. (1996) Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348, 1196-1201.
20. Phillips-Howard PA & West LJ (1990) Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. Journal of the Royal Society of Medicine 83, 82-85.
21. Weise A, Grundler S, Zaumsegel D et al. (2004) Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clinical Laboratory 50, 141-148.
22. WHO (2001) Antimalarial Drug Combination Therapy. Report of a WHO technical consultation. (WHO/CDS/RBM/2001.35) WHO, Geneva.